Posted by Michael Wonder on 22 Aug 2017
Pharmaxis announces positive recommendation for broader Bronchitol access in Australia
18 August 2017 - Pharmaceutical research company Pharmaxis today announced it has received a positive recommendation from the PBAC in Australia for expanded reimbursement of its drug Bronchitol for the treatment of cystic fibrosis.
The PBAC, the government’s independent advisory body on medicine reimbursement, has cleared the way for PBS funding of Bronchitol in combination with reimbursed Pulmozyme after considering a submission from Pharmaxis at its most recent meeting.
Pharmaxis CEO Mr Gary Phillips said, “The submission for broader access to Bronchitol was strongly supported by the cystic fibrosis community with patients, families, patient organisations and cystic fibrosis clinic teams taking part in the feedback process. We look forward to discussing the positive PBAC recommendation with the Australian government to enable the PBS listing that will allow appropriate patients taking Pulmozyme to add reimbursed Bronchitol to their treatment regime.”
